Middey Damian
Pediatric Endocrinology · Wellington, FLNPI 1013938422
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,150 of the $23,316 with a category attached, or 65.0%. 36 manufacturers reported payments, led by AbbVie at 58.8% of the total. Reporting peaked in 2020 at $8,392 and has fallen 83.5% since, to $1,388 in 2025.
Across 360 payments — averaging $64.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Dexcom, Inc.$3K
- Novo Nordisk$1K
- Ascendis Pharma Endocrinology Inc$831
- Insulet Corporation$561
- Tandem Diabetes Care, Inc.$483
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$15,15065%
- Travel & lodging$1,1195%
- Food & beverage$6,67429%
- Education$3732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $13,719 |
| Dexcom, Inc. | 9 | $3,375 |
| Novo Nordisk | 71 | $1,046 |
| Ascendis Pharma Endocrinology Inc | 23 | $831 |
| Insulet Corporation | 19 | $561 |
| Tandem Diabetes Care, Inc. | 17 | $483 |
| Tolmar Pharmaceuticals, Inc. | 36 | $360 |
| Sanofi-aventis U.S. LLC | 14 | $330 |
| Xeris Pharmaceuticals, Inc. | 12 | $245 |
| Tolmar, Inc. | 12 | $219 |
| Lilly USA, LLC | 11 | $202 |
| Medtronic(2 entities) | 8 | $195 |
| Abbott | 9 | $171 |
| Zealand Pharma US, Inc. | 5 | $153 |
| Neurocrine Biosciences, Inc. | 6 | $150 |
| BETA Bionics, Inc. | 6 | $133 |
| Endo Pharmaceuticals Inc. | 7 | $115 |
| Sandoz | 5 | $108 |
| Amphastar Pharmaceuticals, Inc. | 5 | $92 |
| IBSA Pharma Inc. | 5 | $92 |
| Lifescan, Inc. | 5 | $88 |
| Arbor Pharmaceuticals, Inc. | 4 | $87 |
| Pfizer | 4 | $84 |
| Ultragenyx Pharmaceutical Inc. | 4 | $74 |
| Ferring Pharmaceuticals Inc. | 4 | $72 |
| Biomarin Pharmaceutical Inc. | 2 | $55 |
| Endo USA, Inc. | 2 | $44 |
| Vistapharm, Inc. | 2 | $42 |
| Mannkind Corporation | 2 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $33 |
| Azurity Pharmaceuticals, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Companion Medical, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Eton Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lupron Depot$13,265
- DEXCOM CGM$3,119
- SKYTROFA$357
- Sogroya$250
- Omnipod$235
- Wegovy$229
- DEXCOM G7 GSS (161)$150
- DEXCOM STELO GLUCOSE BIOSENSOR$150
- Minimed 670G System$121
- t:slim X2 insulin pump$120
- t-slim insulin pump$102
How this compares
$23,316 in reported general payments places this provider in the 85th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Wellington
- Joshua YangOrlando$846K
- Henry RodriguezTampa$211K
- Dorothy ShulmanTampa$104K
- Michael HallerGainesville$102K
- Alejandro DiazMiami$101K
- Samuel FreedmanPembroke Pines$71K
- Jennifer MillerGainesville$57K
- Miladys Palau CollazoPort St Lucie$54K
- Laura JacobsenGainesville$36K
- Matthew BensonOrlando$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.